Company
Intech Biopharm Corp
Headquarters: Taipei, Taiwan
Employees: 89
Market Cap
TW$3.81 Billion
TWD as of Jan. 1, 2025
US$116.2 Million
Intech Biopharm Corp Categories
Taiwan Healthcare BiotechnologyTaiwan Healthcare Taiwan Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Intech Biopharm Corporation focuses on developing and manufacturing generic drugs to treat respiratory diseases. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform to treat asthma and chronic pulmonary obstructive disease; and dry powder inhaler. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation is headquartered in Taipei, Taiwan.
Stocks & Indices
Intech Biopharm Corp has the following listings and related stock indices.
Stock: TWSE: 6461 wb_incandescent